


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/625,989
				Filing Date	07/24/2003
				First Named Inventor	Kenneth D. R. SETCHELL et al.
				Art Unit	1614
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	CHM-013M2



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
AP		US	5,942,539	08/29/1999	Hughes, Jr. et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
AP		WO	02/11675	02/14/2002	Zelickson, M., D., Brian D.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
-----------------------	----------------------------	--------------------	------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

2

Complete if Known

Application Number	10/625,989
Filing Date	07/24/2003
First Named Inventor	Kenneth D. R. SETCHELL et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	CHM-013M2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US	Number - Kind Code² (if known)			
AP		US	4,390,559	06/28/1983	Zilliken	
AP		US	5,141,746	08/25/1992	Fleury et al.	
AP		US	5,352,384	10/04/1994	Shen	
AP		US	5,424,331	06/13/1995	Shlyankevich	
AP		US	5,523,087	06/04/1996	Shlyankevich	
AP		US	6,565,864 B2	05/20/2003	Pillai et al.	
AP		US	6,628,543	10/28/2003	Kang et al.	
AP		US	2002/0019377 A1	02/14/2002	Jenkins et al.	
AP		US	2002/0160064	10/31/2002	Zulli et al.	
AP		US	2003/0027772 A1	02/06/2003	Breton	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T²
		Country Code³	Number⁴-Kind Code⁵ (if known)				
AP		Japan	H02-124883	05/14/1990	Kitasato Institute	Partial English Translation	
AP		WO	93/23069	11/25/1993	Kelly, Graham, Edmund		
AP		WO	94/23716	10/27/1994	Tufts University School of Medicine		
AP		WO	96/10341	04/11/1996	Van Haaster, Joseph, Nicolas		
AP		WO	97/06273	02/20/1997	Fermalogic, Inc.		
AP		WO	98/48790	11/05/1998	Anticancer, Inc.		
AP		WO	02/087517	11/07/2002	Beiersdorf AG	Abstract	
AP		WO	02/089757	11/14/2002	Beiersdorf AG	Abstract	
AP		WO	04/022023	03/18/2004	Novogen Research		
AP		WO	04/026274	04/01/2004	Novogen Research PTY Ltd.		
AP		WO	04/039327 A2	05/13/2004	Colorado State University Research Foundation, Brigham Young University; Children's Hospital Medical Center		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T²
AP		LUND, TD et al., Equol is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback, Biol. Reprod., 2004 Apr; 70(4) 1188-95, E-Pub. 2003 Dec. 17	
AP		ATKINSON, C. et al, In Vitro Incubation of Human Feces with Daidzein and Antibiotics Suggests Interindividual Differences in the Bacteria Responsible for Equol Production, Amer. Society for Nutritional Sciences, 134:596-599, March 2004	
AP		SETCHELL, Kenneth, D.R.. et al. Phytoestrogens: The Biochemistry, Physiology, and Implications for Human Health of Soy Isoflavones, Am J. Clin Nutri 1998, Pgs. 1333S-1346S	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/625,989
				Filing Date	07/24/2003
				First Named Inventor	Kenneth D. R. SETCHELL et al.
				Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	CHM-013M2

AP		ALDERCREUTZ, H. et al, Determination of Urinary Lignans And Phytoestrogen Metabolites, Potential Antiestrogen and Anticarcinogens in Urine of Women on Various Habitual Diets, J. Steroid Biochem, Vol. 25, pp 791-797 (1996)	Abstract
AP		THOMPSON, M.A. et al., Characterization of the Estrogenic Properties of A Nonsteroidal Estrogen, Equol, Extracted from Urine of Pregnant Macaques Biol Reprod, Nov 1984; 31: 705 - 713.	
AP		HEDLUND, T.E. et al., Soy Isoflavonoid Equol Modulates the Growth of Benign and Malignant Prostatic Epithelial Cells in Vitro, The Prostate 54:68-78 (2003) accepted May 14, 2002	
AP		DUNCAN, A. M. et al., Premenopausal Equol Excretors Show Plasma Hormone Profiles Associated with Lowered Risk of Breast Cancer , Cancer Epidemiol, Biomarkers Prev Vol. 9: 581-586. June, 2000.	
AP		HWANG, J. et al., The Phytoestrogen Equol Increases Nitric Oxide Availability by Inhibiting Superoxide Production: An Antioxidant Mechanism for Cell-Mediated LDL Modification, Free Radical Biology & Medicine, Vol. 34, No. 10, pp. 1271-1282, (2003)	
AP		MUTHYALA, R. S., Equol, a Natural Estrogenic Metabolite from Soy Isofavones: Convenient Preparation and Resolution of R- and S- Equols and Their Differing Binding and Biological Activity Through Estrogen Receptors Alpha and Beta, Bioorganic & Medicinal Chemistry 12 pp 1559-1567 (2004), accepted November 19, 2003	
AP		SATHYAMOORTHY, N. et al., Differential Effects of Dietary Phyto-oestrogens Daidzein and Equol on Human Breast Cancer MCF-7 Cells, European Journal of Cancer, Volume 33, Issue 14, December 1997, Pages 2384-2389	Abstract
AP		OGAWARA, H., A specific Inhibitor for Tyrosine Protein Kinase from Pseudomonas, The Journal of Antibiotics, Vol. 39(4), Apr. 1936, 606-608	

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
--------------------	----------------------------	-----------------	------------

Attorney Docket No. CHM-013M2

COPENDING U.S. PATENT APPLICATIONS				
Examiner Initials	Applicant(s)	Serial No.	Filing Date	Atty. Docket No.
AP	Setchell, et al.	10/625,934	07/24/2003	CHM-013M1
AP	Lephart, et al	10/533,045	04/28/2005	CSU-001M
AP	Lephart, et al	11/059,951	02/17/2005	CSU-002M

STATEMENT
SEP 17 2004
PATENT & TRADEMARK OFFICE

1	of	1
---	----	---

Application Number	10/625,989
Filing Date	07/24/2003
First Named Inventor	Kenneth D.R. Setchell, et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	CHM-013M1

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	To
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T ²

10/02/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete If Known</i>	
				Application Number	10/625,989
				Filing Date	July 24, 2003
				First Named Inventor	K. D. R. SETCHELL et al.
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	CHM-013M2


U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)				
AP 						

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
-----------------------	----------------------------	--------------------	------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/625,989
				Filing Date	July 24, 2003
				First Named Inventor	K. D. R. SETCHELL et al.
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	CHM-013M2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code² (if known)				
AP		US-	6,518,301 B1	02/11/2003	Barlaam et al.	
		US-				
		US-				
		US-				
		US-				
		US				
		US				
		US				
		US				
		US-				

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
-----------------------	----------------------------	--------------------	------------



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/625,989
Filing Date	July 24, 2003
First Named Inventor	K. D. R. SETCHELL et al.
Art Unit	
Examiner Name	
Attorney Docket Number	CHM-013M2

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
AP		US-	4,814,346	03/21/1989	Albert et al.	
		US-	5,498,631	03/12/1996	Gorbach et al.	
		US-	5,726,034	03/10/1998	Bryan et al.	
		US-	5,733,926	03/31/1998	Gorbach	
		US-	5,804,234	09/08/1998	Suh et al.	
		US-	5,849,798	12/15/1998	Charpentier et al.	
		US-	5,855,892	01/05/1999	Potter et al.	
		US-	5,952,374	09/14/1999	Clarkson et al.	
		US-	5,958,946	09/28/1999	Styczynski et al.	
		US-	5,990,291	11/23/1999	Waggle et al.	
		US-	6,020,471	02/01/2000	Johns et al.	
		US-	6,054,636	04/25/2000	Fader	
		US-	6,060,070	05/09/2000	Gorbach	
		US-	6,083,526	07/04/2000	Gorbach	
		US-	6,146,668	11/14/2000	Kelly et al.	
		US-	6,159,959	12/12/2000	Miller	
		US-	6,258,856	07/10/2001	Chamberlain et al.	
		US-	6,326,366 B1	12/04/2001	Potter et al.	
		US-	6,340,703 B1	01/22/2002	Kelly	
		US-	6,375,994 B1	04/23/2002	Paul et al.	
		US-	6,509,043	01/21/2003	Hoie	
		US-	6,518,301 B1	02/11/2003	Barlaam et al.	
		US-	6,544,566	04/08/2003	Waggle et al.	
		US-	6,562,380 B1	05/13/2003	Kelly	
		US-	6,599,536	07/29/2003	Keliy	
		US	2002/0001565 A1	01/03/2002	Shapiro	
		US	2002/0019377 A1	02/14/2002	Jenkins et al.	
		US	2002/0035074 A1	03/21/2002	Kelly	
		US	2003/0027772 A1	02/06/2003	Breton	
AP		US-	Re. 34,457	11/30/1993	Okamoto et al.	

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
-----------------------	----------------------------	--------------------	------------



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known	
				Application Number	10/625,989
				Filing Date	July 24, 2003
				First Named Inventor	K. D. R. SETCHELL et al.
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	CHM-013M2


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
AP		AU 20006896 A4	05/11/2000	Praxis Pharmaceuticals Australia Pty Ltd.		Abstract only
		WO 98/21946 A1	05/28/1998	Internutria, Inc.		
		WO 98/26784 A1	06/25/1998	University of Sydney		
		WO 99/49851 A1	10/07/1999	Bioresponse L.L.C.		
		WO 99/61028 A1	12/02/1999	Gorbach		
		WO 00/13661 A1	03/16/2000	Avon Products Inc.		
		WO 00/30663 A1	06/02/2000	Nutri Pharma ASA		
		WO 00/41491 A2	07/20/2000	Nutrahealth Ltd.		
		WO 00/49009 A1	08/24/2000	Novogen Research Pty. Ltd.		
		WO 00/62774 A1	10/26/2000	Board of Trustees, Southern Illinois Univ.		
		WO 02/03976 A2	01/17/2002	American Home Prod. Corp.		
		WO 02/03977 A2	01/17/2002	American Home Prod. Corp.		
		WO 02/03992 A2	01/17/2002	American Home Prod. Corp.		
AP		WO 02/053108 A2	07/11/2002	Unilever PLC		
		WO 02/062367 A1	08/15/2002	Metagenics, Inc.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T ²
AP		SETCHELL, Kenneth D. R. et al., Bioavailability of Pure Isoflavones In Healthy Humans and Analysis of Commercial Soy Isoflavone Supplements. American Society for Nutritional Sciences, 2001, pgs. 1362S-1375S	
AP		BROWN, Nadine M. et al., Animal Models Impacted by Phytoestrogens in Commercial Chow: Implications for Pathways Influenced by Hormones, Laboratory Investigation, May 2001, Vol. 81, No. 5, pgs. 735-747	
AP		SETCHELL, Kenneth D. R. et al., Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability, Am J Clin Nutri 2002, 76, pgs. 447-453.	
AP		WAHÄLÄ, Kristiina et al., Synthesis of the [³ H] - Labelled Urinary Lignans, Enterolactone and Enterodiol, and the Phytoestrogen Daidzein and its Metabolites Equol and O-Demethyl-angolensin, J. Chem. Soc. Perkin Trans. I, 1986, pgs. 95-98.	
AP		KOHLI, J.C. et al., Specific separation of equol from estrogens by thin-layer chromatography, Journal of Chromatography, 129 (1976), pgs. 473-474, Elsevier Scientific Publ. Co., Amsterdam.	
AP		LAMBERTON, John A. et al., Catalytic Hydrogenation of Isoflavones. The Preparation of (±)-Equol and Related Isoflavans, Aust. J. Chem., 1978, 31, pgs. 455-457	

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
-----------------------	----------------------------	--------------------	------------



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

<p align="center">Complete if Known</p>							
				Application Number	10/625,989		
				Filing Date	July 24, 2003		
				First Named Inventor	K. D. R. SETCHELL et al.		
				Art Unit			
				Examiner Name			
Sheet	3	of	3	Attorney Docket Number	CHM-013M2		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS - Con't

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T ²
AP		ATSUTANE, Ohta et al., A combination of Dietary Fructooligosaccharides and Isoflavone Conjugates Increases Femoral Bone Mineral Density and Equol Production in Ovariectomized Mice, American Society for Nutritional Sciences, 2002, pgs. 2048-2054.	
		SETCHELL, KDR et al., Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease, The American Journal of Clinical Nutrition 40, 09/1984, pgs. 569-578.	
		ALVIRA, E. et al., Molecular modeling study for chiral separation of equol enantiomers by β -cyclodextrin, Chemical Physics 240 (1999), pgs. 101-108, Elsevier Science B.V.	
		ANDERSON, Edith L. et al., The Identification of Equol as 7-Hydroxy-3-(4'-Hydroxyphenyl) Chroman, and the Synthesis of Racemic Equol Methyl Ether, J. Biol. Chem. 127: 649-56 (1939)	
		Chiralcel® OD, Instruction Sheet, Daicel Chemical Industries, Ltd., Japan, 5/1/1995	
		Chiralcel® OD, Instruction Sheet, Daicel Chemical Industries, Ltd., Exton, PA, 12/6/1994	
		SETCHELL, K.D.R. et al., Dietary Phytoestrogens and Their Effect on Bone: Evidence from In Vitro and In Vivo, Human Observational, and Dietary Intervention Studies, Am J Clin Nutr, 2003; 78 (suppl): 593S-609S	
		Sigma-Aldrich webpage. Equol, Product No. 45405, July 10, 2003	
		Sigma-Aldrich webpage. (\pm)-Equol, Product No. 45405, October 23, 2003	
		BOWEY, E. et al., Metabolism of Isoflavones and Lignans by the Gut Microflora: a Study in Germ-Free and Human Flora Associated Rats, Food Chem Toxicol., 2003 May; 41 (5): 631-6.	Abstract only
		RAFII F. et al., Variations in Metabolism of the Soy Isoflavonoid Daidzen by Human Intestinal Microfloras from Different Individuals, Arch Microbiol., 2003 Jul; 180(1): 11-6, Epub 2003 May 29.	Abstract only
		WIDYARINI S. et al., Isoflavonoid Compounds from Red Clover (Trifolium Pratense) Protect from Inflammation and Immune Suppression Induced by UV Radiation, Photochem Photobiol, 2001 Sep; 74(3): 465-70	Abstract only
		ROWLAND I.R. et al., Interindividual Variation in Metabolism of Soy Isoflavones and Lignans: Influence of Habitual Diet on Equol Production by the Gut Microflora, Nutr Cancer, 2000; 36(1): 27-32	Abstract only
		KAZIRO R. et al., The Oestrogenicity of Equol in Sheep, J Endocrinol, 1984 Dec; 103(3): 395-9	Abstract only
		SETCHELL, K.D.R. et al., Bioavailability, Disposition, and Dose-Response Effects of Soy Isoflavones When Consumed by Healthy Women at Physiologically Typical Dietary Intakes, American Society for Nutritional Sciences, 2003, pgs. 1027-1035	
✓		SETCHELL, K.D.R. et al., The Clinical Importance of the Metabolite Equol - A Clue to the Effectiveness of Soy and Its Isoflavones, American Society for Nutritional Sciences, 2002, pgs. 3577-3584	
AP		AXELSON, M. et al., The Identification of the Weak Oestrogen Equol [7-hydroxy-3-(4'-hydroxyphenyl)chroman] in Human Urine, Biochem. J. 1982. 201, 353-357, Printed in Great Britain	

Examiner Signature	/Alton Pryor/ (10/02/2006)	Date Considered	10/02/2006
-----------------------	----------------------------	--------------------	------------

Attorney Docket No. CHM-013M2



COPENDING U.S. PATENT APPLICATIONS

Examiner Initial	Applicant(s)	Serial No.	Filing Date	Attorney Docket No.
AP	SETCHELL et al.	10/625,934	07/24/03	CHM-013M1